Bio-Bridge Science to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged 
      in the commercial development of vaccines for the prevention and 
      treatment of human infectious diseases, announced today that Dr. Liang 
      Qiao, the Company’s chief executive officer, 
      will present at the Rodman & Renshaw 10th 
      Annual Healthcare Conference, on Wednesday, November 12, 2008, at 9:30 
      a.m. Eastern time in the Louis room at the Palace Hotel, New York City.
    
    
      The presentation will give an overview of the Company, a summary of its 
      strategic plan, as well as, discuss recent events such as the completion 
      of an acquisition of Xinheng Baide Biotechnology and the execution of a 
      Memorandum of Understanding to form a Joint Venture in China.
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.